Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 3.4.24.3 - microbial collagenase

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Adenocarcinoma
[New direct assay method of type IV collagenase in tissue homogenate and biochemical role of collagenase against type I, and IV collagens to the invasion of the stomach and lung cancer]
Adenoma
[Study of type I and IV collagenase activity in human thyroid diseases]
Anthrax
Inhibition of bacterial carbonic anhydrases and zinc proteases: from orphan targets to innovative new antibiotic drugs.
Anti-Glomerular Basement Membrane Disease
Heterogeneity of antibodies in Goodpasture syndrome reacting with type IV collagen.
Arthritis
Decrease in expression of bone morphogenetic proteins 4 and 5 in synovial tissue of patients with osteoarthritis and rheumatoid arthritis.
Innervation of the patella. An immunohistochemical study in mice.
Arthritis, Rheumatoid
[Detection of collagenase in passive haemagglutination using collagen-coated erythrocytes (author's transl)]
Bell Palsy
DTB Select: 2 | February 2016.
Bone Resorption
H-31 human breast cancer cells stimulate type I collagenase production in osteoblast-like cells and induce bone resorption.
Brain Edema
Metalloproteinase inhibition blocks edema in intracerebral hemorrhage in the rat.
Modeling intracerebral hemorrhage in mice: injection of autologous blood or bacterial collagenase.
Brain Injuries
Cannabinoid CB2 receptor stimulation attenuates brain edema and neurological deficits in a germinal matrix hemorrhage rat model.
Breast Neoplasms
H-31 human breast cancer cells stimulate type I collagenase production in osteoblast-like cells and induce bone resorption.
Bursitis
Can Collagenase Be Used in the Treatment of Adhesive Capsulitis?
Clostridium histolyticum (AA4500) for the Treatment of Adhesive Capsulitis of the Shoulder: A Randomised Double-Blind, Placebo-Controlled Study for the Safety and Efficacy of Collagenase - Single Site Report.
CORR(®) ORS Richard A. Brand Award: Clinical Trials of a New Treatment Method for Adhesive Capsulitis.
Carcinoma
Collagenase-1 injection improved tumor distribution and gene expression of cationic lipoplex.
Detection of mRNAs encoding collagenase I and stromelysin 2 in carcinomas of the head and neck by in situ hybridization.
Increased stromelysin 3 gene expression is associated with increased local invasiveness in head and neck squamous cell carcinomas.
[New direct assay method of type IV collagenase in tissue homogenate and biochemical role of collagenase against type I, and IV collagens to the invasion of the stomach and lung cancer]
[Study of type I and IV collagenase activity in human thyroid diseases]
Carcinoma, Papillary
[Study of type I and IV collagenase activity in human thyroid diseases]
Carcinoma, Squamous Cell
Collagenase activity in cultures of rat prostate carcinoma.
[New direct assay method of type IV collagenase in tissue homogenate and biochemical role of collagenase against type I, and IV collagens to the invasion of the stomach and lung cancer]
Cerebral Hemorrhage
Effect of fucoidan treatment on collagenase-induced intracerebral hemorrhage in rats.
Enhanced pulmonary inflammation following experimental intracerebral hemorrhage.
Experimental intracerebral hemorrhage in rats. Magnetic resonance imaging and histopathological correlates.
Intracerebral hemorrhage in the rat: effects of hematoma aspiration.
Intrastriatal injection of autologous blood or clostridial collagenase as murine models of intracerebral hemorrhage.
Metalloproteinase inhibition blocks edema in intracerebral hemorrhage in the rat.
Modeling intracerebral hemorrhage in mice: injection of autologous blood or bacterial collagenase.
Pharmacogenomic effects of apolipoprotein e on intracerebral hemorrhage.
Protective effects of free radical inhibitors in intracerebral hemorrhage in rat.
Rapid Loss of Perihematomal Cell Viability in the Collagenase Intracerebral Hemorrhage Model.
Sheng-Di-Da-Huang Decoction Inhibited Inflammation Expressed in Microglia after Intracerebral Hemorrhage in Rats.
Simultaneous detection and separation of hyperacute intracerebral hemorrhage and cerebral ischemia using amide proton transfer MRI.
Therapeutic benefit of human umbilical cord derived mesenchymal stromal cells in intracerebral hemorrhage rat: implications of anti-inflammation and angiogenesis.
Cerebral Palsy
Intramuscular injection of collagenase clostridium histolyticum may decrease spastic muscle contracture for children with cerebral palsy.
Chondrosarcoma
Partial characterization of procollagen messenger ribonucleic acid in a murine chondrosarcoma.
Colorectal Neoplasms
Imaging intratumoral convection: pressure-dependent enhancement in chemotherapeutic delivery to solid tumors.
Congenital Abnormalities
At what cost is collagenase clostridium histolyticum viable for treating Peyronie's disease in a public healthcare system?
Collagenase clostridium histolyticum for the treatment of Peyronie's disease: a prospective Italian multicentric study.
Collagenase clostridium histolyticum: a novel medical treatment for Peyronie's disease.
Collagenase Treatment of Dupuytren's Disease with Minimum 5-Year Follow-Up: Recurrence, Reintervention, and Satisfaction.
Collagenase versus placebo in the treatment of Peyronie's disease: a double-blind study.
Factors Associated With Erectile Dysfunction and the Peyronie's Disease Questionnaire in Patients With Peyronie Disease.
How Atypical Penile Curvature Influence Clinical Outcomes in Patients with Peyronie's Disease Receiving Collagenase Clostridium Histolyticum Therapy?
Long-term Curvature Deformity Characterization in Men Previously Treated With Collagenase Clostridium Histolyticum for Peyronie's Disease, Subgrouped by Penile Plaque Calcification.
Long-Term Safety and Curvature Deformity Characterization in Patients Previously Treated with Collagenase Clostridium Histolyticum for Peyronie's Disease.
Minimally Invasive Treatment of Peyronie's Disease: Evidence-Based Progress.
Review of Management Options for Patients With Atypical Peyronie's Disease.
Safety Profile of Collagenase Clostridium Histolyticum Stratified by Degree of Penile Curvature in Patients With Peyronie Disease.
Surgical correction of persistent Peyronie's disease following collagenase clostridium histolyticum treatment.
The Influence of Indentation Deformity on Outcomes With Intralesional Collagenase Clostridium Histolyticum Monotherapy for Peyronie's Disease.
Treatment of Peyronie's Disease With Collagenase Clostridium histolyticum and Vacuum Therapy: A Randomized, Open-Label Pilot Study.
Treatment-related Outcomes for Patients With Atypical Peyronie's Disease Using Xiaflex Injections.
Contracture
Acute double flexor tendon ruptures following injection of collagenase clostridium histolyticum (Xiapex) for Dupuytren's contracture.
Analysis of Efficacy and Safety of Treatment With Collagenase Clostridium histolyticum Among Subgroups of Patients With Dupuytren Contracture.
Collagenase clostridium histolyticum for Dupuytren's contracture.
Collagenase Clostridium histolyticum for the Treatment of Distal Interphalangeal Joint Contractures in Dupuytren Disease.
Collagenase clostridium histolyticum in Dupuytren's contracture: a systematic review.
Collagenase Clostridium Histolyticum Injection for Dupuytren Contracture: 2-Year Follow-up.
Collagenase Clostridium Histolyticum versus Limited Fasciectomy for Dupuytren's Contracture: Outcomes from a Multicenter Propensity Score Matched Study.
Collagenase Clostridium histolyticum. Short-term benefit in Dupuytren's contracture, unknown long-term risks.
Collagenase Treatment for Dupuytren Disease of the Thumb and First Web.
Collagenase Treatment of Dupuytren's Disease with Minimum 5-Year Follow-Up: Recurrence, Reintervention, and Satisfaction.
Current role of the collagenase Clostridium histolyticum in Dupuytren's disease treatment.
Determining clinically important changes in range of motion in patients with Dupuytren's Contracture: secondary analysis of the randomized, double-blind, placebo-controlled CORD I study.
Dupuytren Contractures: An Update of Recent Literature.
Durability of Collagenase Treatment for Dupuytren Disease of the Thumb and First Web After at Least 2 Years' Follow-Up.
Efficacy and safety of collagenase clostridium histolyticum in the treatment of proximal interphalangeal joints in dupuytren contracture: combined analysis of 4 phase 3 clinical trials.
Efficacy and safety of concurrent collagenase clostridium histolyticum injections for multiple Dupuytren contractures.
Enzyme injection as nonsurgical treatment of Dupuytren's disease.
Examining the efficacy and maintenance of contracture correction after collagenase clostridium histolyticum treatment for Dupuytren's disease.
Hand function 5 years after treatment with collagenase Clostridium histolyticum injection for Dupuytren's disease.
In Vitro Study of Novel Collagenase (XIAFLEX®) on Dupuytren's Disease Fibroblasts Displays Unique Drug Related Properties.
Injectable collagenase clostridium histolyticum for Dupuytren's contracture.
Intramuscular injection of collagenase clostridium histolyticum may decrease spastic muscle contracture for children with cerebral palsy.
Isolated and Spontaneous Correction of Proximal Interphalangeal Joint Contractures in Dupuytren's Disease: An Exploratory Analysis of the Efficacy and Safety of Collagenase Clostridium histolyticum.
Late Complications of Clinical Clostridium Histolyticum Collagenase Use in Dupuytren's Disease.
Letter Regarding "Dupuytren Contracture Recurrence Following Treatment With Collagenase Clostridium Histolyticum (CORDLESS [Collagenase Option for Reduction of Dupuytren Long-Term Evaluation of Safety Study]): 5-Year Data".
Morphological patterns of the pretendinous cord in Dupuytren's disease: a predictor of clinical outcome?
Multiple Recurrences in Aggressive Forms of Dupuytren's Disease-Can Patients Benefit from Repeated Selective Fasciectomy?
Needle fasciotomy for Dupuytren's contracture- a prospective cohort study of 58 fingers with a median follow-up of 6.5 years.
One year follow-up after treatment with CCH for Dupuytren's disease: A prospective view.
Outcome of Dupuytren Contractures After Collagenase Clostridium Histolyticum Injection: A Single-institution Experience.
Outcome of Dupuytren's Contractures After Collagenase Clostridium Histolyticum Injection: A Single Institution Experience.
Percutaneous Needle Fasciotomy Versus Collagenase Treatment for Dupuytren Contracture: A Randomized Controlled Trial with a Two-Year Follow-up.
Risk Factors for Skin Tearing in Collagenase Treatment of Dupuytren Contractures.
Risk Factors for Skin Tears Following Collagenase Clostridium histolyticum to Treat Dupuytren Contractures.
Scientific understanding and clinical management of Dupuytren disease.
Skin Laceration in Collagenase Clostridium histolyticum Treatment for Dupuytren's Contracture.
The efficacies and limitations of fasciectomy and collagenase clostridium histolyticum in Dupuytren's contracture management: A meta-analysis.
The Efficacy and Safety of Concurrent Collagenase Clostridium Histolyticum Injections for 2 Dupuytren Contractures in the Same Hand: A Prospective, Multicenter Study.
[Collagenase clostridum histolyticum in the management of Dupuytren's contracture].
Dehydration
Evaluation of collagen crosslinking techniques.
Dermatitis
Toxic dermatitis secondary to treatment with collagenase clostridium histolyticum for Dupuytren´s disease.
Dermatitis, Contact
Contact dermatitis with clostridiopeptidase A contained in Noruxol ointment.
Diabetes Mellitus
Clinical outcomes associated with serial sharp debridement of diabetic foot ulcers with and without clostridial collagenase ointment.
Enzymatic Debridement of Chronic Nonischemic Diabetic Foot Ulcers: Results of a Randomized, Controlled Trial.
Diabetes Mellitus, Type 2
Enzymatic Debridement of Chronic Nonischemic Diabetic Foot Ulcers: Results of a Randomized, Controlled Trial.
Diabetic Foot
Clinical outcomes associated with serial sharp debridement of diabetic foot ulcers with and without clostridial collagenase ointment.
Clinical Outcomes for Diabetic Foot Ulcers Treated with Clostridial Collagenase Ointment or with a Product Containing Silver.
Clostridial Collagenase for the Management of Diabetic Foot Ulcers: Results of Four Randomized Controlled Trials.
Cost-effectiveness of clostridial collagenase ointment on wound closure in patients with diabetic foot ulcers: economic analysis of results from a multicenter, randomized, open-label trial.
Enzymatic Debridement of Chronic Nonischemic Diabetic Foot Ulcers: Results of a Randomized, Controlled Trial.
Erratum to: Cost-effectiveness of clostridial collagenase ointment on wound closure in patients with diabetic foot ulcers: economic analysis of results from a multicenter, randomized, open-label trial.
Health Care Spending in Patients With Stage 3 and Stage 4 Pressure Injuries and Patients With Diabetic Foot Ulcers Treated Early With Clostridial Collagenase Ointment: A Retrospective Data Review.
Diabetic Retinopathy
Enzyme-assisted vitrectomy with bacterial collagenase. Pilot human studies.
Dupuytren Contracture
"Collagenase Clostridium Histolyticum for Dupuytren Contracture: Comparing Single and Concurrent Injections."
A post hoc analysis of Dupuytren contracture treated with collagenase Clostridium histolyticum across disease stages.
A single injection of collagenase clostridium histolyticum for the treatment of moderate Dupuytren's contracture: a 2?year follow-up of 47 patients.
Acute double flexor tendon ruptures following injection of collagenase clostridium histolyticum (Xiapex) for Dupuytren's contracture.
Adverse effects associated with collagenase clostridium histolyticum in Dupuytren disease: A prospective study.
Adverse Effects of Collagenase in the Treatment of Dupuytren Disease: A Systematic Review.
Analysis of Efficacy and Safety of Treatment With Collagenase Clostridium histolyticum Among Subgroups of Patients With Dupuytren Contracture.
Anesthesia for collagenase clostridium histolyticum injection in patients with dupuytren disease: A cohort analysis.
Assessing Potential Cross-Reactivity of Human Endogenous Matrix Metalloproteinases (MMPs) with Collagenase Clostridium Histolyticum (CCH) Antibodies in Human Serum for Patients with Dupuytren's Contracture.
Budget impact analysis in Spanish patients with Dupuytren's contracture: Fasciectomy vs. collagenase Clostridium histolyticum.
Can collagenase effectiveness in Dupuytren's contracture be improved by using ultrasound-guided Injection? A comparative study.
Changes in Provider Treatment Patterns for Dupuytren's Contracture: Analysis of Trends in Medicare Beneficiaries.
Clostridium histolyticum collagenase in the treatment of Dupuytren's contracture.
Cold Intolerance Following Collagenase Clostridium histolyticum Treatment for Dupuytren Contracture.
Cold intolerance following collagenase Clostridium histolyticum treatment for Dupuytren contracture: a molecular mechanism.
Collagenase clostridium histolyticum for dupuytren contracture: patterns of use and effectiveness in clinical practice.
Collagenase clostridium histolyticum for Dupuytren's contracture.
Collagenase Clostridium histolyticum for the Treatment of Distal Interphalangeal Joint Contractures in Dupuytren Disease.
Collagenase clostridium histolyticum for the treatment of Dupuytren's contracture: systematic review and economic evaluation.
Collagenase clostridium histolyticum in Dupuytren's contracture: a systematic review.
Collagenase Clostridium histolyticum in patients with Dupuytren's contracture: results from POINT X, an open-label study of clinical and patient-reported outcomes.
Collagenase Clostridium Histolyticum Injection for Dupuytren Contracture: 2-Year Follow-up.
Collagenase clostridium histolyticum injection for the treatment of Dupuytren's contracture.
Collagenase Clostridium histolyticum Injection Therapy Improves Health-related Quality of Life in Patients with Dupuytren's Disease.
Collagenase Clostridium Histolyticum Injection with Precise Needle Length Adjusted by Silicone Tube Interposition for Dupuytren Contracture.
Collagenase Clostridium Histolyticum versus Limited Fasciectomy for Dupuytren's Contracture: Outcomes from a Multicenter Propensity Score Matched Study.
Collagenase Clostridium histolyticum. Short-term benefit in Dupuytren's contracture, unknown long-term risks.
Collagenase Treatment for Dupuytren Disease of the Thumb and First Web.
Collagenase treatment of Dupuytren's contracture using a modified injection method.
Collagenase Treatment of Dupuytren's Disease with Minimum 5-Year Follow-Up: Recurrence, Reintervention, and Satisfaction.
Comparison of Treatment Outcomes after Collagenase Injection and Percutaneous Needle Fasciotomy for Dupuytren's Contracture: Objective and Subjective Comparisons with a 3-Year Follow-Up.
Complications Following Collagenase Treatment for Dupuytren Contracture.
Cost Comparison of Collagenase Clostridium Histolyticum and Fasciectomy for Treatment of Dupuytren's Contracture in the Australian Health System.
Cost-effectiveness of Recurrent Dupuytren Contracture Treatment.
Current role of the collagenase Clostridium histolyticum in Dupuytren's disease treatment.
Delayed manipulation after collagenase clostridium histolyticum injection for Dupuytren contracture.
Determining clinically important changes in range of motion in patients with Dupuytren's Contracture: secondary analysis of the randomized, double-blind, placebo-controlled CORD I study.
Discussion: Collagenase Clostridium Histolyticum for Dupuytren Contracture: Comparing Single and Concurrent Injections.
Does collagenase injection disrupt or digest the Dupuytren's cord: a magnetic resonance imaging study.
DTB Select: 2 | February 2016.
Dupuytren contracture recurrence following treatment with collagenase clostridium histolyticum (CORDLESS study): 3-year data.
Dupuytren Contracture Recurrence Following Treatment With Collagenase Clostridium histolyticum (CORDLESS [Collagenase Option for Reduction of Dupuytren Long-Term Evaluation of Safety Study]): 5-Year Data.
Dupuytren disease: an evolving understanding of an age-old disease.
DupuytrEn Treatment EffeCtiveness Trial (DETECT): a protocol for prospective, randomised, controlled, outcome assessor-blinded, three-armed parallel 1:1:1, multicentre trial comparing the effectiveness and cost of collagenase clostridium histolyticum, percutaneous needle fasciotomy and limited fasciectomy as short-term and long-term treatment strategies in Dupuytren's contracture.
Dupuytren's disease: using needles more across the world.
Durability of Collagenase Treatment for Dupuytren Disease of the Thumb and First Web After at Least 2 Years' Follow-Up.
Early outcomes of a sequential series of 144 patients with Dupuytren's contracture treated by collagenase injection using an increased dose, multi-cord technique.
Efficacy and adverse effects of collagenase use in the treatment of Dupuytren's disease: a meta-analysis.
Efficacy and safety of collagenase clostridium histolyticum for Dupuytren disease nodules: a randomized controlled trial.
Efficacy and safety of collagenase clostridium histolyticum in the treatment of proximal interphalangeal joints in dupuytren contracture: combined analysis of 4 phase 3 clinical trials.
Efficacy and safety of collagenase Clostridium histolyticum injection for Dupuytren contracture: report of 40 cases.
Efficacy and safety of collagenase clostridium histolyticum injection for Dupuytren contracture: short-term results from 2 open-label studies.
Efficacy and safety of collagenase Clostridium histolyticum injection for Dupuytren's contracture in non-Caucasian Japanese patients (CORD-J Study): the first clinical trial in a non-Caucasian population.
Efficacy and safety of collagenase treatment for Dupuytren's disease: 2-year follow-up results.
Efficacy of collagenase Clostridium histolyticum injection for Dupuytren's contracture in East-Asian population.
Efficacy of collagenase in patients who did and did not have previous hand surgery for Dupuytren's contracture.
Enzyme injection as nonsurgical treatment of Dupuytren's disease.
Erratum: Healthcare Costs and Resource Use of Patients with Dupuytren Contracture Treated with Collagenase Clostridium Histolyticum or Fasciectomy: A Propensity Matching Analysis [Corrigendum].
Examining the efficacy and maintenance of contracture correction after collagenase clostridium histolyticum treatment for Dupuytren's disease.
Five-year results after collagenase treatment of Dupuytren disease.
Functional outcome of collagenase injections compared with fasciectomy in treatment of Dupuytren's contracture.
Hand function 5 years after treatment with collagenase Clostridium histolyticum injection for Dupuytren's disease.
Healthcare Costs and Resource Use of Patients with Dupuytren Contracture Treated with Collagenase Clostridium Histolyticum or Fasciectomy: A Propensity Matching Analysis.
Injectable collagenase Clostridium histolyticum as a nonsurgical treatment for Dupuytren's disease.
Injectable collagenase clostridium histolyticum for Dupuytren's contracture.
Injectable collagenase Clostridium histolyticum: a new nonsurgical treatment for Dupuytren's disease.
Injectable Collagenase Versus Percutaneous Needle Fasciotomy for Dupuytren Contracture in Proximal Interphalangeal Joints: A Randomized Controlled Trial.
Isolated and Spontaneous Correction of Proximal Interphalangeal Joint Contractures in Dupuytren's Disease: An Exploratory Analysis of the Efficacy and Safety of Collagenase Clostridium histolyticum.
Late Complications of Clinical Clostridium Histolyticum Collagenase Use in Dupuytren's Disease.
Limited Fasciectomy Versus Collagenase Clostridium histolyticum for Dupuytren Contracture: A Propensity Score Matched Study of Single Digit Treatment With Minimum 5 Years of Telephone Follow-Up.
Measurement properties of the German Unité Rhumatologique des Affections de la Main (URAM) scale in patients treated for Dupuytren's disease.
Needle fasciotomy for Dupuytren's contracture- a prospective cohort study of 58 fingers with a median follow-up of 6.5 years.
New insights into the immediate outcome of collagenase injections for Dupuytren's contracture.
Nonsurgical treatment of Dupuytren's contracture: 1-year US post-marketing safety data for collagenase clostridium histolyticum.
Outcome of Dupuytren Contractures After Collagenase Clostridium Histolyticum Injection: A Single-institution Experience.
Outcomes and Early Recurrence Following Enzymatic (Collagenase) Treatment of Moderate and Severe Dupuytren Contractures.
Pain Associated With Treatment of Dupuytren Contracture With Collagenase Clostridium histolyticum.
Percutaneous Needle Fasciotomy versus Collagenase Injection for Dupuytren's Contracture: A Systematic Review of Comparative Studies.
Percutaneous Needle Fasciotomy Versus Collagenase Treatment for Dupuytren Contracture: A Randomized Controlled Trial with a Two-Year Follow-up.
Phalangeal fracture leading to digital amputation, sustained during manipulation for Dupuytren's disease as part of clostridial collagenase treatment.
Postapproval clinical experience in the treatment of Dupuytren's contracture with collagenase clostridium histolyticum (CCH): the first 1,000 days.
Prospective observation of Clostridium histolyticum collagenase for the treatment of Dupuytren's disease in 788 patients: the Austrian register.
Prospective randomized controlled trial comparing 1- versus 7-day manipulation following collagenase injection for dupuytren contracture.
Range of motion, postoperative rehabilitation and patient satisfaction in MCP and PIP joints affected by Dupuytren Tubiana stage 1-3: collagenase enzymatic fasciotomy or limited fasciectomy? A clinical study in 52 patients.
Recurrent Dupuytren's disease after fasciectomy and collagenase injection are histologically indistinguishable.
Resource utilisation associated with single digit Dupuytren's contracture treated with either surgery or injection of collagenase Clostridium histolyticum.
Retraction: Late complications of clinical Clostridium histolyticum collagenase use in Dupuytren's disease.
Return-to-Function Following Treatment of Dupuytren Contracture With Collagenase Clostridium Histolyticum Versus Fasciectomy.
Safety and tolerability of collagenase Clostridium histolyticum and fasciectomy for Dupuytren's contracture.
Salvage palmar fasciectomy after initial treatment with collagenase clostridium histolyticum.
Seven-year clinical outcomes after collagenase injection in patients with Dupuytren's disease: A prospective study.
Short-term efficacy and safety of collagenase injection for Dupuytren's contracture: Therapy protocol for successful outcomes in a clinical setting.
Skin graft loss resulting from collagenase clostridium histolyticum treatment of dupuytren contracture: case report and review of the literature.
Skin Laceration in Collagenase Clostridium histolyticum Treatment for Dupuytren's Contracture.
Surgical findings in the treatment of Dupuytren's disease after initial treatment with clostridial collagenase (Xiaflex).
The Effects of Collagenase Clostridium histolyticum on Plantar Fibromatosis: A Case Study.
The efficacies and limitations of fasciectomy and collagenase clostridium histolyticum in Dupuytren's contracture management: A meta-analysis.
The efficacy and safety of collagenase clostridium histolyticum in the treatment of patients with moderate Dupuytren's contracture.
The emerging role of Clostridium histolyticum collagenase in the treatment of Dupuytren disease.
The influence of skin tears following collagenase treatment of Dupuytren's disease on treatment outcomes.
The use of Collagenase Clostridium Histolyticum in the management of Dupuytren's contracture-outcomes of a pilot study in a District General Hospital setting.
Toxic dermatitis secondary to treatment with collagenase clostridium histolyticum for Dupuytren´s disease.
Treatment of dupuytren disease with injectable collagenase in a veteran population: a case series at the department of veterans affairs new jersey health care system.
Treatment of Dupuytren's Contracture With Collagenase: A Systematic Review.
Treatment of Recurrent Dupuytren Contracture in Joints Previously Effectively Treated With Collagenase Clostridium histolyticum.
Use of resources and costs associated with the treatment of Dupuytren's contracture at an orthopedics and traumatology surgery department in Denia (Spain): collagenase clostridium hystolyticum versus subtotal fasciectomy.
What is the better treatment for single digit dupuytren's contracture: surgical release or collagenase clostridium histolyticum (Xiapex) injection?
[Collagenase clostridum histolyticum in the management of Dupuytren's contracture].
[Comparative Cost Effectiveness of Clostridium Histolyticum Collagenase (Xiapex®) and Partial Fasciectomy for the Treatment of Dupuytren's Contracture in Austria].
[Long-term experience with Collagenase Clostridium Histolyticum (CCH, Xiapex®) for the treatment of Dupuytren's contracture: lessons learned].
[Treatment of Dupuytren's disease with collagenase Clostridium histolyticum].
Epidermolysis Bullosa Acquisita
Epidermolysis bullosa acquisita antigen: relationship between the collagenase-sensitive and -insensitive domains.
Epidermolysis Bullosa Dystrophica
Inhibition of collagenase type I expression by psoralen antisense oligonucleotides in dermal fibroblasts.
Erectile Dysfunction
The 32nd Annual J.P. Morgan Healthcare Conference (January 13-16, 2014 - San Francisco, California, USA): Auxilium Pharmaceuticals.
Exanthema
Toxic dermatitis secondary to treatment with collagenase clostridium histolyticum for Dupuytren´s disease.
Fibromatosis, Plantar
Collagenase Clostridium histolyticum injection for plantar fibromatosis (Ledderhose disease).
The Effects of Collagenase Clostridium histolyticum on Plantar Fibromatosis: A Case Study.
Foot Ulcer
Clinical outcomes associated with serial sharp debridement of diabetic foot ulcers with and without clostridial collagenase ointment.
Clinical Outcomes for Diabetic Foot Ulcers Treated with Clostridial Collagenase Ointment or with a Product Containing Silver.
Clostridial Collagenase for the Management of Diabetic Foot Ulcers: Results of Four Randomized Controlled Trials.
Cost-effectiveness of clostridial collagenase ointment on wound closure in patients with diabetic foot ulcers: economic analysis of results from a multicenter, randomized, open-label trial.
Enzymatic Debridement of Chronic Nonischemic Diabetic Foot Ulcers: Results of a Randomized, Controlled Trial.
Erratum to: Cost-effectiveness of clostridial collagenase ointment on wound closure in patients with diabetic foot ulcers: economic analysis of results from a multicenter, randomized, open-label trial.
Health Care Spending in Patients With Stage 3 and Stage 4 Pressure Injuries and Patients With Diabetic Foot Ulcers Treated Early With Clostridial Collagenase Ointment: A Retrospective Data Review.
Gas Gangrene
Bacterial collagen-binding domain targets under-twisted regions of collagen.
Ca2+-induced linker transformation leads to a compact and rigid collagen-binding domain of Clostridium histolyticum collagenase.
Giant Cell Tumors
Response to hormones of cells cultured from human giant cell tumors of bone.
Glomerulonephritis
Heterogeneity of antibodies in Goodpasture syndrome reacting with type IV collagen.
Isolation of the specific glomerular basement membrane antigen involved in Goodpasture syndrome.
Graves Disease
[Study of type I and IV collagenase activity in human thyroid diseases]
Infections
BMP9-induced osteogenetic differentiation and bone formation of muscle-derived stem cells.
Rabbit corneal damage produced by Pseudomonas aeruginosa infection.
Ischemic Stroke
Simultaneous detection and separation of hyperacute intracerebral hemorrhage and cerebral ischemia using amide proton transfer MRI.
Joint Instability
Animal models of arthritis in NOS2-deficient mice.
The relation between cartilage damage and osteophyte size in a murine model for osteoarthritis in the knee.
Keratoconus
Increase in type I and type IV collagenolytic activity in primary cultures of keratoconus cornea.
Leiomyoma
Extracellular matrix and Hippo signaling as therapeutic targets of antifibrotic compounds for uterine fibroids.
Injectable Clostridium histolyticum collagenase as a potential treatment for uterine fibroids.
Loss of stiffness in collagen-rich uterine fibroids after digestion with purified collagenase Clostridium histolyticum.
Using rheology to quantify the effects of localized collagenase treatments on uterine fibroid digestion.
Leukemia
Mutations that abrogate transactivational activity of the feline leukemia virus long terminal repeat do not affect virus replication.
Leukemia, Feline
Mutations that abrogate transactivational activity of the feline leukemia virus long terminal repeat do not affect virus replication.
Liver Cirrhosis
Extracellular matrix-penetrating nanodrill micelles for liver fibrosis therapy.
Liver Diseases
Relationship between serum and hepatic 7S fragments of type IV collagen in chronic liver disease.
Lung Injury
Chorioamnionitis increases matrix metalloproteinase-8 concentrations in bronchoalveolar lavage fluid from preterm babies.
Lung Neoplasms
[New direct assay method of type IV collagenase in tissue homogenate and biochemical role of collagenase against type I, and IV collagens to the invasion of the stomach and lung cancer]
Lymphatic Metastasis
[Study of type I and IV collagenase activity in human thyroid diseases]
Melanoma
A matrix metalloproteinase-1/protease activated receptor-1 signaling axis promotes melanoma invasion and metastasis.
Suppression of basement membrane type IV collagen degradation and cell invasion in human melanoma cells expressing an antisense RNA for MMP-1.
Suppression of type I collagenase expression by antisense RNA in melanoma cells results in reduced synthesis of the urokinase-type plasminogen activator receptor.
Muscle Spasticity
Intramuscular injection of collagenase clostridium histolyticum may decrease spastic muscle contracture for children with cerebral palsy.
Neoplasm Metastasis
Inhibition of collagenase type I expression by psoralen antisense oligonucleotides in dermal fibroblasts.
[Collagenases and cancers]
[Study of type I and IV collagenase activity in human thyroid diseases]
Neoplasms
Antitumor promotion and antiinflammation: down-modulation of AP-1 (Fos/Jun) activity by glucocorticoid hormone.
Collagenase-1 injection improved tumor distribution and gene expression of cationic lipoplex.
Degradation of fibrillar collagen in a human melanoma xenograft improves the efficacy of an oncolytic herpes simplex virus vector.
Detection of a secreted metalloprotease within the nuclei of liver cells.
Imaging intratumoral convection: pressure-dependent enhancement in chemotherapeutic delivery to solid tumors.
Inhibition of collagenase type I expression by psoralen antisense oligonucleotides in dermal fibroblasts.
Invasive tumors induce c-ets1 transcription factor expression in adjacent stroma.
Phenotypic alterations in fos-transgenic mice correlate with changes in Fos/Jun-dependent collagenase type I expression. Regulation of mouse metalloproteinases by carcinogens, tumor promoters, cAMP, and Fos oncoprotein.
Profiling, comparison and validation of gene expression in gastric carcinoma and normal stomach.
Response to hormones of cells cultured from human giant cell tumors of bone.
Surface modulation of polymeric nanocarriers enhances the stability and delivery of proteins and small molecules.
Synthesis and collagenase inhibition of new glycosides of aranciamycinone: the aglycon of the naturally occurring antibiotic aranciamycin.
Targeted disruption of the c-fos gene demonstrates c-fos-dependent and -independent pathways for gene expression stimulated by growth factors or oncogenes.
Temperature-dependent metastasis of the Lucke renal carcinoma and its significance for studies on mechanisms of metastasis.
Unique anti-activator protein-1 activity of retinoic acid receptor beta.
[Collagenases and cancers]
[New direct assay method of type IV collagenase in tissue homogenate and biochemical role of collagenase against type I, and IV collagens to the invasion of the stomach and lung cancer]
Osteoarthritis
Animal models of arthritis in NOS2-deficient mice.
Calcitonin gene-related peptide, substance P and GAP-43/B-50 immunoreactivity in the normal and arthrotic knee joint of the mouse.
Glial activation in the collagenase model of nociception associated with osteoarthritis.
Induction of osteoarthritis by intra-articular injection of collagenase in mice. Strain and sex related differences.
The relation between cartilage damage and osteophyte size in a murine model for osteoarthritis in the knee.
[Histopathological study of the effects of intra-articular injection of triamcinolone acetonide on temporomandibular joint osteoarthrosis in goats]
Osteolysis
H-31 human breast cancer cells stimulate type I collagenase production in osteoblast-like cells and induce bone resorption.
Osteosarcoma
Discordant effects of activator protein-1 transcription factor on gene regulation, invasion, and metastasis in spontaneous, radiation-induced, and fos-induced osteosarcomas.
Pancreatic Neoplasms
Heterogeneities of attachment, chemotaxis, and protease production among clones with different metastatic potentials from a human pancreatic cancer cell line.
Penile Induration
"Doc, if it were you, what would you do?": a survey of Men's Health specialists' personal preferences regarding treatment modalities.
A modified technique for intralesional injection of collagenase Clostridium histolyticum for Peyronie's disease results in reduced procedural morbidity using a standardized hematoma classification rubric.
A state-of-art review on collagenase Clostridium Histolyticum and Peyronie's disease: drug profile, clinical evidence and safety outcomes.
Analysis of the clinical safety of intralesional injection of collagenase Clostridium histolyticum (CCH) for adults with Peyronie's disease (PD).
At what cost is collagenase clostridium histolyticum viable for treating Peyronie's disease in a public healthcare system?
Baseline characteristics from an ongoing phase 3 study of collagenase clostridium histolyticum in patients with Peyronie's disease.
Canadian provider perspectives on Collagenase Clostridium histolyticum for the treatment of Peyronie's disease and the impact of its discontinuation.
Changes in the Effects of Peyronie's Disease After Treatment With Collagenase Clostridium histolyticum: Male Patients and Their Female Partners.
Characteristics of Men With Peyronie's Disease and Collagenase Clostridium Histolyticum Treatment Failure: Predictors of Surgical Intervention and Outcomes.
Characteristics predictive of response to collagenase clostridium histolyticum for Peyronie's disease: a review of the literature.
Clinical Efficacy of Collagenase Clostridium Histolyticum in the Treatment of Peyronie's Disease by Subgroups: Results From Two Large, Double-Blind, Randomized, Placebo-Controlled, Phase 3 Studies.
Clinical efficacy, safety, and tolerability of collagenase clostridium histolyticum in the treatment of Peyronie's disease from 2 large double-blind, randomized, placebo-controlled phase 3 studies.
Clinical Experience with Penile Traction Therapy among Men Undergoing Collagenase Clostridium Histolyticum for Peyronie's Disease.
Clinical safety and effectiveness of collagenase clostridium histolyticum injection in patients with Peyronie's disease: a phase 3 open-label study.
Clostridial collagenase and Peyronie disease.
Collagenase Clostridium histolyticum for the pharmacological management of Peyronie's disease.
Collagenase Clostridium Histolyticum for the Treatment of Peyronie's Disease: A 'Real World' Clinical Perspective.
Collagenase clostridium histolyticum for the treatment of Peyronie's disease: a prospective Italian multicentric study.
Collagenase Clostridium histolyticum for the Treatment of Peyronie's Disease: The Development of This Novel Pharmacologic Approach.
Collagenase Clostridium histolyticum in the management of Peyronie's disease: a review of the evidence.
Collagenase Clostridium histolyticum in the treatment of Peyronie's disease: patient selection and perspectives.
Collagenase Clostridium Histolyticum in the Treatment of Peyronie's Disease: Review of a Minimally Invasive Treatment Option.
Collagenase clostridium histolyticum intralesional injections for the treatment of Peyronie's disease: a safety profile.
Collagenase clostridium histolyticum: a novel medical treatment for Peyronie's disease.
Collagenase Clostridium Histolyticum: A Review in Peyronie's Disease.
Collagenase for Peyronie's disease experimental studies.
Collagenase versus placebo in the treatment of Peyronie's disease: a double-blind study.
Comparative Cost-effectiveness of Surgery, Collagenase Clostridium Histolyticum, and Penile Traction Therapy in Men with Peyronie's Disease in an Era of Effective Clinical Treatment.
Complications and other concerns with intralesional injection therapy with collagenase clostridium histolyticum for Peyronie's disease.
Conservative management of suspected fractures in men undergoing collagenase clostridium histolyticum for Peyronie's Disease is not associated with worsening of erectile function.
Continuing Collagenase Clostridium Histolyticum Injections Among Initial Nonresponders Results in Significant Curvature Improvements in the Majority of Peyronie's Disease Men.
Correction to: Efficacy of Collagenase Clostridium histolyticum (Xiapex®) in Patients with the Acute Phase of Peyronie's Disease.
Discontinuation from Collagenase Clostridium histolyticum Therapy for Peyronie's Disease: Review and Single-Center Cohort Analysis.
Editorial Comment: Comparative Cost-effectiveness of Surgery, Collagenase Clostridium Histolyticum, and Penile Traction Therapy in Men with Peyronie's Disease in an Era of Effective Clinical Treatment.
Editorial Comment: Impact of the advent of collagenase clostridium histolyticum on the surgical management of Peyronie's disease: a population-based analysis.
Effect of collagenase Clostridium histolyticum on penile vascular and morphological parameters in patients with Peyronie's disease.
Efficacy and safety of collagenase Clostridium histolyticum in Peyronie's disease following a modified treatment protocol.
Efficacy of Collagenase Clostridium histolyticum (Xiapex®) in Patients with the Acute Phase of Peyronie's Disease.
Efficacy of Combined Collagenase Clostridium histolyticum and RestoreX Penile Traction Therapy in Men with Peyronie's Disease.
Evaluating collagenase Clostridium histolyticum administration protocols in the treatment of Peyronie's disease.
Expanding the role of injectable collagenase clostridium histolyticum for the treatment of active phase Peyronie's disease.
Experience in the use of collagenase clostridium histolyticum in the management of Peyronie's disease: current data and future prospects.
How Atypical Penile Curvature Influence Clinical Outcomes in Patients with Peyronie's Disease Receiving Collagenase Clostridium Histolyticum Therapy?
Humoral immune responses in Peyronie's disease patients receiving clostridial collagenase therapy.
Impact of Number of Cycles of Collagenase Clostridium Histolyticum on Outcomes in Patients With Peyronie's Disease.
Impact of the Advent of Collagenase Clostridium Histolyticum on the Surgical Management of Peyronie's Disease: A Population-Based Analysis.
Intralesional Collagenase Clostridium Histolyticum Causes Meaningful Improvement in Men with Peyronie's Disease: Results of a Multi-Institutional Analysis.
Intralesional Injection of Collagenase Clostridium histolyticum May Increase the Risk of Late-Onset Penile Fracture.
Intralesional Injection of Interferon-?2b Improves Penile Curvature in Men with Peyronie's Disease Independent of Plaque Location.
Lateral herniation during treatment with collagenase Clostridium histolyticum (Xiaflex) for Peyronie's disease.
Limited success with clostridium collagenase histolyticum following FDA approval for the treatment of Peyronie's disease.
Long-term Curvature Deformity Characterization in Men Previously Treated With Collagenase Clostridium Histolyticum for Peyronie's Disease, Subgrouped by Penile Plaque Calcification.
Long-Term Safety and Curvature Deformity Characterization in Patients Previously Treated with Collagenase Clostridium Histolyticum for Peyronie's Disease.
Management of Peyronie's disease with collagenase Clostridium histolyticum in the acute phase.
Managing complications of collagenase Clostridium histolyticum (CCH) injection.
Multi-institutional Prospective Analysis of Intralesional Injection of Collagenase Clostridium Histolyticum, Tunical Plication, and Partial Plaque Excision and Grafting for the Management of Peyronie's Disease.
Optimizing collagenase Clostridium histolyticum therapy for Peyronie's disease using a novel approach with percutaneous needle tunnelling.
Outcomes of Surgery in Peyronie's Disease Following Intralesional Collagenase Clostridium Histolyticum Injections.
Patient perspectives on Peyronie's disease: results of poststudy interviews from a phase 2 trial of collagenase clostridium histolyticum.
Patient-reported outcomes from a single-centre prospective post-marketing study on Collagenase Clostridium Histolyticum injections for Peyronie's disease.
Peyronie's Disease and Injectable Collagenase Clostridium histolyticum: Safety, Efficacy, and Improvements in Subjective Symptoms.
Peyronie's disease: contemporary review of non-surgical treatment.
Phase 2b study of the clinical efficacy and safety of collagenase Clostridium histolyticum in patients with Peyronie disease.
Plaque Calcification: An Important Predictor of Collagenase Clostridium Histolyticum Treatment Outcomes for Men With Peyronie's Disease.
Predictive Factors of Patients' and Their Partners' Sexual Function Improvement After Collagenase Clostridium Histolyticum Injection for Peyronie's Disease: Results From a Multi-Center Single-Arm Study.
Predictors of treatment success after collagenase Clostridium histolyticum injection for Peyronie's disease: development of a nomogram from a multicentre single-arm, non-placebo controlled clinical study.
Racial variations in response to intralesional collagenase clostridium histolyticum in men with Peyronie's disease.
Re: Baseline Characteristics from an Ongoing Phase 3 Study of Collagenase Clostridium Histolyticum in Patients with Peyronie's Disease.
Re: Clinical Efficacy of Collagenase Clostridium histolyticum in the Treatment of Peyronie's Disease by Subgroups: Results from Two Large, Double-blind, Randomized, Placebo-controlled, Phase III Studies.
Re: clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies.
Re: clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies: M. Gelbard, I. Goldstein, W. J. Hellstrom, C. G. McMahon, T. Smith, J. Tursi, N. Jones, G. J. Kaufman and C. C. Carson, III J Urol 2013; 190: 199-207.
Re: Clinical Experience with Penile Traction Therapy among Men Undergoing Collagenase Clostridium histolyticum for Peyronie Disease.
Re: Clinical Experience with Penile Traction Therapy among Men Undergoing Collagenase Clostridium Histolyticum for Peyronie Disease.
Re: Impact of the Advent of Collagenase Clostridium Histolyticum on the Surgical Management of Peyronie's Disease: A Population-Based Analysis.
Re: Multi-Institutional Prospective Analysis of Intralesional Injection of Collagenase Clostridium histolyticum, Tunical Plication, and Partial Plaque Excision and Grafting for the Management of Peyronie's Disease.
Re: Outcomes of Surgery in Peyronie's Disease following Intralesional Collagenase Clostridium histolyticum Injections.
Re: Peyronie's Disease and Injectable Collagenase Clostridium histolyticum: Safety, Efficacy, and Improvements in Subjective Symptoms.
Re: Plaque Calcification: An Important Predictor of Collagenase Clostridium Histolyticum Treatment Outcomes for Men with Peyronie's Disease.
Re: Plaque Calcification: An Important Predictor of Collagenase Clostridium histolyticum Treatment Outcomes for Men with Peyronie's Disease.
Re: Results of SMSNA survey regarding complications following intralesional injection therapy with collagenase clostridium histolyticum for Peyronie's disease.
Re: Safety and Effectiveness of Collagenase Clostridium Histolyticum in the Treatment of Peyronie's Disease Using a New Modified Shortened Protocol.
Re: Surgical Correction of Persistent Peyronie's Disease following Collagenase Clostridium histolyticum Treatment.
Restoration of Penile Function and Patient Satisfaction with Intralesional Collagenase Clostridium Histolyticum Injection for Peyronie's Disease.
Results of SMSNA Survey Regarding Complications Following Intralesional Injection Therapy With Collagenase Clostridium Histolyticum for Peyronie's Disease.
Results of SMSNA survey regarding complications following intralesional injection therapy with collagenase clostridium histolyticum for Peyronie's disease.
Review of Intralesional Collagenase Clostridium Histolyticum Injection Therapy and Related Combination Therapies in the Treatment of Peyronie's Disease (an Update).
Role of collagenase clostridium histolyticum in Peyronie's disease.
Safety and effectiveness of collagenase clostridium histolyticum in the treatment of Peyronie's disease using a new modified shortened protocol.
Safety and Efficacy of Collagenase Clostridium Histolyticum in Peyronie's Disease Men With Ventral Curvatures.
Safety and Efficacy of Collagenase Clostridium histolyticum in the Treatment of Acute Phase Peyronie's Disease: A Multi-institutional Analysis.
Safety and Efficacy of Collagenase Clostridium histolyticum in the Treatment of Acute-Phase Peyronie's Disease.
Safety and Efficacy Study of Collagenase Clostridium Histolyticum Applied With an Intensive Protocol in the Treatment of Peyronie's Disease.
Safety of Collagenase Clostridium histolyticum Injection Therapy for Peyronie Disease in Patients Continuing Antiplatelet or Anticoagulant Therapy.
Safety Profile of Collagenase Clostridium Histolyticum Stratified by Degree of Penile Curvature in Patients With Peyronie Disease.
Second cycle of intralesional Collagenase Clostridium histolyticum for Peyronie's disease using the modified shortened protocol: Results from a retrospective analysis.
Self-reported Clinical Meaningfulness Early in the Treatment Course Predicts Objective Outcomes in Men Undergoing Collagenase Clostridium histolyticum Injections for Peyronie Disease.
Sixty years in the making: collagenase Clostridium histolyticum, from benchtop to FDA approval and beyond.
Successful Treatment of Residual Curvature in Peyronie's Disease in Men Previously Treated with Intralesional Collagenase Clostridium Histolyticum.
Surgical correction of persistent Peyronie's disease following collagenase clostridium histolyticum treatment.
Surgical outcomes after collagenase Clostridium histolyticum failure in patients with Peyronie's disease in a multicenter clinical study.
Survey of patient and partner satisfaction following collagenase Clostridium histolyticum treatment for Peyronie's disease.
The 32nd Annual J.P. Morgan Healthcare Conference (January 13-16, 2014 - San Francisco, California, USA): Auxilium Pharmaceuticals.
The Effects of Collagenase Clostridium histolyticum on Plantar Fibromatosis: A Case Study.
The History of Collagenase Clostridium Histolyticum.
The Impact of Clostridium Histolyticum Collagenase on the Prevalence and Management of Peyronie's Disease in the United States.
The Influence of Indentation Deformity on Outcomes With Intralesional Collagenase Clostridium Histolyticum Monotherapy for Peyronie's Disease.
The Management of Penile Fracture: a Review of the Literature with Special Consideration for Patients Undergoing Collagenase Clostridium Histolyticum Injection Therapy.
The use of collagenase in the treatment of Peyronie's disease.
The use of intralesional clostridial collagenase injection therapy for Peyronie's disease: a prospective, single-center, non-placebo-controlled study.
Treatment of Peyronie's disease via preoperative intralesional collagenase clostridium histolyticum followed by placement of an inflatable penile prosthesis: the new standard of care?
Treatment of Peyronie's Disease With Collagenase Clostridium histolyticum and Vacuum Therapy: A Randomized, Open-Label Pilot Study.
Treatment of peyronie's disease with combination of clostridium histolyticum collagenase and penile traction therapy: a prospective, multicenter, single-arm study.
Treatment Patterns and Healthcare Outcomes with Collagenase Clostridium Histolyticum vs Surgery in Peyronie's Disease: A Retrospective Claims Database Analysis.
Treatment-related Outcomes for Patients With Atypical Peyronie's Disease Using Xiaflex Injections.
Variation in collagenase Clostridium histolyticum practice patterns: a Survey of ISSM Members.
Xiaflex for Treatment of Peyronie's Disease.
[Collagenase clostridium histolyticum for Peyronie's disease: A new minimally invasive and effective treatment].
[Efficacy and safety of local injections treatments for Peyronie's disease: Review of the literature].
Periodontitis
Salivary collagenase. Origin, characteristics and relationship to periodontal health.
Placenta, Retained
Equine retained placenta: technique for and tolerance to umbilical artery injections of collagenase.
Polycystic Kidney Diseases
Acceleration of bone formation during fracture healing by poly(Pro-Hyp-Gly)10 and basic fibroblast growth factor containing polycystic kidney disease and collagen-binding domains from Clostridium histolyticum collagenase.
Acceleration of callus formation during fracture healing using basic fibroblast growth factor-kidney disease domain-collagen-binding domain fusion protein combined with allogenic demineralized bone powder.
Basic Fibroblast Growth Factor Fused with Tandem Collagen-Binding Domains from Clostridium histolyticum Collagenase ColG Increases Bone Formation.
Basic Fibroblast Growth Factor-Anchored Multilayered Mesenchymal Cell Sheets Accelerate Periosteal Bone Formation.
Effect of Freeze-Dried Allograft Bone with Human Basic Fibroblast Growth Factor Containing a Collagen-Binding Domain from Clostridium Histolyticum Collagenase on Bone Formation after Lumbar Posterolateral Fusion Surgery in Rats.
Enhancement of periosteal bone formation by basic fibroblast-derived growth factor containing polycystic kidney disease and collagen-binding domains from Clostridium histolyticum collagenase.
Solution structure of clostridial collagenase H and its calcium-dependent global conformation change.
Pressure Ulcer
A retrospective study of the effects of clostridial collagenase ointment and negative pressure wound therapy for the treatment of chronic pressure ulcers.
Clostridial collagenase ointment and medicinal honey utilization for pressure ulcers in US hospitals.
Comparative Effectiveness of Clostridial Collagenase Ointment to Medicinal Honey for Treatment of Pressure Ulcers.
Cost effectiveness of adding clostridial collagenase ointment to selective debridement in individuals with stage IV pressure ulcers.
Economic analysis and budget impact of clostridial collagenase ointment compared with medicinal honey for treatment of pressure ulcers in the US.
Treating pressure ulcers with clostridial collagenase ointment: Results from the US Wound Registry.
Pterygium
[Electron-microscopic and biochemical characteristics of pterygia (author's transl)]
Respiratory Distress Syndrome
Chorioamnionitis increases matrix metalloproteinase-8 concentrations in bronchoalveolar lavage fluid from preterm babies.
Retinopathy of Prematurity
Enzyme-assisted vitrectomy with bacterial collagenase. Pilot human studies.
Rhabdomyosarcoma
[5-fluorouracil inhibits bacterial collagenase and the collagenolytic system of a human rhabdomyosarcoma]
Sarcoma
CD4+ T-cells from mice immunized to syngeneic sarcomas recognize distinct, non-shared tumor antigens.
Folding of collagen IV.
Sarcoma, Yoshida
Synthesis and collagenase inhibition of new glycosides of aranciamycinone: the aglycon of the naturally occurring antibiotic aranciamycin.
Skin Neoplasms
Inhibition of collagenase type I expression by psoralen antisense oligonucleotides in dermal fibroblasts.
Stomach Neoplasms
[New direct assay method of type IV collagenase in tissue homogenate and biochemical role of collagenase against type I, and IV collagens to the invasion of the stomach and lung cancer]
Stroke
Effects of selective hypothermia on blood-brain barrier integrity and tight junction protein expression levels after intracerebral hemorrhage in rats.
Synovitis
Decrease in expression of bone morphogenetic proteins 4 and 5 in synovial tissue of patients with osteoarthritis and rheumatoid arthritis.
Tendinopathy
Adipose micro-grafts enhance tendinopathy healing in ovine model: An in vivo experimental perspective study.
Autologous tenocyte therapy for experimental achilles tendinopathy in a rabbit model.
Histopathological study of the infrapatellar fat pad in the rat model of patellar tendinopathy: A basic study.
Pulsed electromagnetic fields improve the healing process of Achilles tendinopathy: a pilot study in a rat model.
The Healing Potential of Plantago lanceolata Ointment on Collagenase-Induced Tendinitis in Burros (Equus asinus)
Tetanus
Bacterial protease inhibitors.
Inhibition of bacterial carbonic anhydrases and zinc proteases: from orphan targets to innovative new antibiotic drugs.
Inhibition of collagenase breakdown of equine corneas by tetanus antitoxin, equine serum and acetylcysteine.
Thyroid Neoplasms
[Study of type I and IV collagenase activity in human thyroid diseases]
Urethral Stricture
Collagenase Clostridium histolyticum (Xiaflex) for the Treatment of Urethral Stricture Disease in a Rat Model of Urethral Fibrosis.
Collagenase Clostridium Histolyticum in the Treatment of Urologic Disease: Current and Future Impact.
Urologic Diseases
Collagenase Clostridium Histolyticum in the Treatment of Urologic Disease: Current and Future Impact.
Varicose Veins
Matrix metalloproteinases in the vein wall.
Vitreoretinopathy, Proliferative
Enzyme-assisted vitrectomy with bacterial collagenase. Pilot human studies.